We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 16,701 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
TIDMOPTI
RNS Number : 9849M
OptiBiotix Health PLC
20 October 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Optibiotix increased investment in SkinBiotix Limited
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces an increase in its investment in its majority owned subsidiary SkinBiotix Limited ("SkinBiotix").
Under the terms of the agreement, OptiBiotix has increased its investment into SkinBiotix, using a Convertible Loan Agreement, with an investment of GBP400k which will provide funding to complete the development and human studies for the first product application, in addition to funding activities to support an Initial Public Offering ("IPO"). The loan will convert should SkinBiotix successfully complete and IPO.
The increased investment will provide SkinBiotix with resources to progress towards an independent listing in line with OptiBiotix's strategy update of 5 July 2016.
SkinBiotix is dedicated to the development of skin biotherapeutics using natural components of the skin microbiome to protect, manage and restore skin health problems. SkinBiotix uses patented technology to address large scale markets in skin health including Cosmetic Skin Care ($121bn); Health Care Acquired Infections ($82bn); Dermatology ($10.2bn) and Wound Care ($18bn).
Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has made strong progress with the development of SkinBiotix. We have built the team, added significant IP and put in place development programmes and plans for human studies with the objective of translating the science into commercial products with large potential global markets. Our belief in the potential of SkinBiotix is demonstrated by this additional investment which will enable SkinBiotix to accelerate its corporate and technical development plans. OptiBiotix believes the scale of the opportunities offered by SkinBiotix's technology in the biotherapeutic space creates the potential for substantial future value enhancement. The directors believe that shareholder value could be maximised as existing shareholders may, in the event of a successful flotation of SkinBiotix, ultimately hold shares directly in both companies."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com Stephen O'Hara, Chief Executive Contact via Walbrook below Cairn Financial Advisers LLP (NOMAD) Tel: 020 7148 7900 Liam Murray / Rebecca Anderson finnCap (Broker) Tel: 020 7220 0500 Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) Tony Quirke (Corporate Broking) Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Mike Wort Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEKLFFQBFBFBX
(END) Dow Jones Newswires
October 20, 2016 02:00 ET (06:00 GMT)
1 Year Optibiotix Health Chart |
1 Month Optibiotix Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions